Check out the positive review of Gilead Sciences Inc's hepatitis C drug - Sofosbuvir given by the ‘U.S. Food and Drug Administration’ (FDA).
Gilead Sciences’ much-anticipated hepatitis C drug, named as Sofosbuvir, has been given the thumbs up by an FDA advisory group. All 15 members of the Food and Drug Administration’s panel of virus experts have voted in favor of approving Sofosbuvir, a daily pill designed to treat several forms of Hepatitis C. Usually FDA follows the recommendations made by its advisory panels, but not required to do so. The FDA is expected to make the final decision regarding the approval of the drug by 8th of December 2013.
Gilead Sciences’ much-anticipated hepatitis C drug, named as Sofosbuvir, has been given the thumbs up by an FDA advisory group. All 15 members of the Food and Drug Administration’s panel of virus experts have voted in favor of approving Sofosbuvir, a daily pill designed to treat several forms of Hepatitis C. Usually FDA follows the recommendations made by its advisory panels, but not required to do so. The FDA is expected to make the final decision regarding the approval of the drug by 8th of December 2013.